Last reviewed · How we verify

NCT04969406

A Prospective Trial of the Intelon BOSS(TM) System

Terminated NA Last updated 10 June 2022
What this trial tests

NA trial testing Brillouin Spectroscopy via BOSS System in Cornea in 23 participants. Terminated before completion.

Timeline
24 July 2021
Primary endpoint
10 December 2021
10 December 2021

Quick facts

Lead sponsorIntelon Optics, Inc
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment23
Start date24 July 2021
Primary completion10 December 2021
Estimated completion10 December 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Intelon Optics, Inc

Who can join

18 and older, any sex, with Cornea or Lens Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, open-label, single-site clinical trial designed to evaluate the repeatability and reproducibility of biomechanical imaging by the BOSS device. Subjects will undergo unilateral biomechanical mapping of the cornea and lens by three BOSS devices operated by three (3) different operators.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cornea

Currently open trials in the same condition.

Other Intelon Optics, Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing